Debbie Rigby rounds up the latest in research news

Patients with underuse or overuse of inhaled corticosteroids have different perceptions and beliefs regarding COPD and inhaled medication

This study explored the perceptions and beliefs of patients with COPD regarding the disease and inhaled medication treatment. A majority of patients did not fully accept their disease, showed little disease knowledge, and many revealed signs of depressive mood and severe fatigue. Overusers reported more grief about decreased participation in daily life and were more frustrated in general. Underusers claimed using less medication because they felt well, did not want to use too much medication, and used their inhalation devices too long.

Patient Preference and Adherence 2018:12 1777–1783.

Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly

The use of low-dose aspirin as a primary prevention strategy in older adults resulted in a significantly higher risk of major hemorrhage and did not result in a significantly lower risk of cardiovascular disease than placebo. Results from the ASPREE study show after a median of 4.7 years of follow-up, the rate of cardiovascular disease did not differ, and the rate of major haemorrhage increased by 38%.

New Engl J Med 2018

Effect of Aspirin on All-Cause Mortality in the Healthy Elderly

Further results from the ASPREE study showed higher all-cause mortality was observed among apparently healthy older adults who received daily aspirin than among those who received placebo and was attributed primarily to cancer-related death. The risk of death from any cause was 14% higher in the aspirin group compared to placebo.

New Engl J Med 2018

Effect of Aspirin on Disability-free Survival in the Healthy Elderly

In the ASPREE trial, aspirin use in healthy elderly persons did not prolong disability-free survival over a period of 5 years but led to a higher rate of major hemorrhage than placebo. The rate of major hemorrhage was 38% higher in the aspirin group than in the placebo group.

New Engl J Med 2018

The Conversation comments